Core Viewpoint - Quantum BioPharma Ltd. is facing a class action lawsuit alleging stock manipulation that has materially harmed its shareholders between January 6, 2021, and October 15, 2025 [1] Company Overview - Quantum BioPharma Ltd. (NASDAQ: QNTM) is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3] - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [3] - Quantum BioPharma retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the marketing of its product unbuzzd™ and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty rate will drop to 3% [3] Legal Actions - Shareholder Paul Durkacz has initiated a class action lawsuit against Quantum BioPharma, claiming that investors were victims of stock manipulation [1] - Quantum BioPharma intends to seek appointment as a lead plaintiff in the class action to protect its shareholders [2] Strategic Investments - The company maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial properties [3]
World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares